This author has not written his bio yet.
But we are proud to say that Andrew Humphreys contributed 3897 entries already.
EVERSANA, a pioneer of next-generation commercial services to the global life sciences industry, announced the acquisition of Accelera Canada and its partner companies Patient Access Solutions, Podium Strategic Partners Inc. and Advocacy Solutions.
People who received the one-dose Johnson & Johnson Covid-19 vaccine may need a booster shot to fend off some of the worrisome coronavirus variants now spreading worldwide, a study suggests.
The U.S. Food and Drug Administration approved AbbVie’s Dalvance (dalbavancin) for acute bacterial skin and skin structure infections in pediatric patients as young as newborns.
The U.S. FDA approved AstraZeneca’s convenient once-a-week glucose-lowering drug Bydureon for 10- to 17-year-olds with type 2 diabetes. According to a study conducted in Canada, one dose of the company’s Covid-19 vaccine developed with Oxford University was 87 percent effective against hospitalization or death related to SARS-CoV-2.
Moderna’s Covid-19 vaccine could become the second shot cleared for adolescent use in the European Union after regulators on July 23 recommended approving Spikevax for 12- to 17-year-olds ahead of U.S. authorities.
A longer gap between doses of Pfizer’s Covid-19 vaccine leads to higher overall antibody levels than a shorter gap, a British study found on July 23, but antibody levels are not sustained for long after the first dose.
Despite reports of a rare neurological disorder appearing in some people who have received Johnson & Johnson’s Covid-19 vaccine, the benefits of its use outweigh the risks, a U.S. Centers for Disease Control and Prevention advisory panel said on July 22.
Endo International Plc agreed to pay $35 million to settle a lawsuit by Tennessee local governments and on behalf of a child allegedly born addicted to painkillers accusing the drugmaker of fueling the opioid epidemic, the company announced July 22.
World Health Organization investigators have attempted to return to the Wuhan lab but are now being blocked by the Chinese government.
The model for healthcare delivery and treatment was upended by the COVID-19 pandemic, as ordinary Americans have learned to take more control of their own care and treatment, harnessing a new class of technology tools that have given individuals unprecedented clout. But patients and healthcare providers still need to partner together for the best outcomes, according to Jim Weiss, founder and CEO of Real Chemistry.
